Not available
Quote | Compugen Ltd. (NASDAQ:CGEN)
Last: | $1.56 |
---|---|
Change Percent: | 3.59% |
Open: | $1.61 |
Close: | $1.56 |
High: | $1.625 |
Low: | $1.5 |
Volume: | 813,122 |
Last Trade Date Time: | 07/05/2024 03:00:00 am |
News | Compugen Ltd. (NASDAQ:CGEN)
2024-07-05 07:18:27 ET More on Roche Roche: Obesity Treatment's Promise Isn't Enough More Of The Same Isn't Good Enough For Roche Roche Is Joining The Obesity Party But Questions Remain Roche's crovalimab wins FDA approval for paroxysmal nocturnal hemoglobinu...
Compugen to Present at Upcoming Antibody Industrial Symposium PR Newswire HOLON, Israel , June 17, 2024 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, t...
Message Board Posts | Compugen Ltd. (NASDAQ:CGEN)
Subject | By | Source | When |
---|---|---|---|
whytestocks: $CGEN News Article - Compugen Doses First Patient in Triple Combination COM701, COM902 | whytestocks | investorshangout | 03/06/2023 3:55:49 PM |
whytestocks: $CGEN News Article - Why Compugen Shares Are Up Today | whytestocks | investorshangout | 02/28/2023 5:30:50 PM |
whytestocks: $CGEN News Article - Compugen Reports Fourth Quarter and Full Year 2022 Results | whytestocks | investorshangout | 02/27/2023 8:20:49 PM |
whytestocks: $CGEN News Article - 4 Cheap Penny Stocks To Buy For Under $1 Right Now | whytestocks | investorshangout | 11/17/2022 7:45:51 PM |
whytestocks: $CGEN News Article - Compugen to Receive Milestone Payment Triggered by AstraZeneca's P | whytestocks | investorshangout | 11/16/2022 3:15:49 PM |
News, Short Squeeze, Breakout and More Instantly...
Compugen to Present at Upcoming Antibody Industrial Symposium PR Newswire HOLON, Israel , June 17, 2024 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, t...
Compugen to Receive Milestone Payment Triggered by Dosing of First Patient in the Second Phase 3 Trial Evaluating Rilvegostomig PR Newswire Phase 3 trial evaluating rilvegostomig as monotherapy and in combination with AstraZeneca and Daiichi Sankyo's datopotamab deruxtecan in ...
A look at the top 10 most actives in the United States Greenwave Technology Solutions Inc. (GWAV) rose 33.8% to $0.0788 on volume of 1,221,538,672 shares Akoustis Technologies Inc. (AKTS) rose 128.8% to $0.3151 on volume of 536,119,838 shares Crown Electrokinetics Corp. (CRKN) rose 3.1% t...